What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
His primary areas of study are Internal medicine, Gastroenterology, Virology, Hepatitis C virus and Immunology.
While the research belongs to areas of Internal medicine, Kenji Ikeda spends his time largely on the problem of Hepatitis B virus, intersecting his research to questions surrounding Hepatitis B.
His Gastroenterology research incorporates elements of Proportional hazards model, Surgery, Retrospective cohort study, Adverse effect and Hazard ratio.
The various areas that Kenji Ikeda examines in his Virology study include Drug resistance and Genotype.
His study in Hepatitis C virus is interdisciplinary in nature, drawing from both Viral disease and Hepatitis C.
His studies deal with areas such as Cancer, Carcinoma and Oncology as well as Hepatocellular carcinoma.
His most cited work include:
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (1199 citations)
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma (964 citations)
- Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. (641 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Gastroenterology, Hepatocellular carcinoma, Virology and Hepatitis C virus are his primary areas of study.
His Internal medicine study combines topics in areas such as Interferon and Immunology.
His study looks at the relationship between Gastroenterology and fields such as Hazard ratio, as well as how they intersect with chemical problems.
His Hepatocellular carcinoma study deals with Oncology intersecting with Lenvatinib.
His work deals with themes such as Polymerase chain reaction and Genotype, which intersect with Virology.
Kenji Ikeda interconnects Viral disease and Alpha interferon in the investigation of issues within Hepatitis C virus.
He most often published in these fields:
- Internal medicine (49.44%)
- Gastroenterology (36.92%)
- Hepatocellular carcinoma (30.18%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (49.44%)
- Gastroenterology (36.92%)
- Hepatocellular carcinoma (30.18%)
In recent papers he was focusing on the following fields of study:
Kenji Ikeda mainly investigates Internal medicine, Gastroenterology, Hepatocellular carcinoma, Virology and Lenvatinib.
The study incorporates disciplines such as Endocrinology and Hepatitis C virus in addition to Internal medicine.
The study incorporates disciplines such as Nonalcoholic fatty liver disease, Retrospective cohort study, Genotype and Hepatitis B virus in addition to Gastroenterology.
In general Hepatocellular carcinoma, his work in Sorafenib is often linked to In patient linking many areas of study.
His studies in Hepatology integrate themes in fields like Surgical oncology, Hepatitis C, Colorectal surgery and Pathology.
His research in Hazard ratio intersects with topics in Carcinoma and Proportional hazards model.
Between 2014 and 2021, his most popular works were:
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (1199 citations)
- UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis. (223 citations)
- The Common and Distinct Features of Brown and Beige Adipocytes (181 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His scientific interests lie mostly in Internal medicine, Gastroenterology, Hepatocellular carcinoma, Hepatology and Virology.
His research on Internal medicine often connects related areas such as Surgery.
His biological study spans a wide range of topics, including Nonalcoholic fatty liver disease, Hepatitis C and Retrospective cohort study, Pathology.
His Hepatocellular carcinoma study integrates concerns from other disciplines, such as Carcinoma, Oncology and Hazard ratio.
His Hepatology study combines topics in areas such as Pibrentasvir, Young adult, Intensive care medicine, Glecaprevir / pibrentasvir and Pediatrics.
Hepatitis C virus is a subfield of Immunology that Kenji Ikeda explores.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
